Lilly Submits Cymbalta(R) Supplemental New Drug Application For Generalized Anxiety Disorder
Thu, 11 May 2006 06:00 AM EST
... Eli Lilly and Company(NYSE: LLY) today announced the recent submission of a supplemental NewDrug Application (sNDA) to the U.S. Food and Drug Administration (FDA) forCymbalta(R) (duloxetine HCl) for the treatment of generalized anxietydisorder. [click link for full article] ...
Related Topics
- Generalized Anxiety Disorder
- Duloxetine
- Anxiety
- Social Phobia
- Adrenal Gland Disorders
- Teriparatide Injection
- Panic Disorder
- Medicare
- Sleep Disorders
- Obsessive Compulsive Disorder
- Genetic Disorders
- Borderline Personality Disorder
- Blood Disorders
- Anxiety disorder
- Communication Disorders
- Dissociative Disorders
- Seizure Disorder
- Language Disorders
- Tiagabine
- Drug Safety

Not Signed In -


